MiR-4458-loaded gelatin nanospheres target COL11A1 for DDR2/SRC signaling pathway inactivation to suppress the progression of estrogen receptor-positive breast cancer

Gelatin nanospheres could be potentially used to deliver miR-4458 and COL11A1 siRNA for DDR2/SRC signaling pathway inactivation to treat ER+ breast cancer.